Albumin-bound paclitaxel: a next-generation taxane
- PMID: 16722814
- DOI: 10.1517/14656566.7.8.1041
Albumin-bound paclitaxel: a next-generation taxane
Abstract
Taxanes are standard treatment for metastatic breast cancer; however, the solvents used as vehicles in these formulations cause severe toxicities. The FDA recently approved a solvent-free formulation of paclitaxel for the treatment of metastatic breast cancer that utilises 130-nanometer albumin-bound (nab) technology (Abraxane; nab-paclitaxel) to circumvent the requirement for solvents. nab-Paclitaxel utilises the natural properties of albumin to reversibly bind paclitaxel, transport it across the endothelial cell and concentrate it in areas of tumour. The proposed mechanism of drug delivery involves, in part, glycoprotein 60-mediated endothelial cell transcytosis of paclitaxel-bound albumin and accumulation in the area of tumour by albumin binding to SPARC (secreted protein, acidic and rich in cysteine). Clinical studies have shown that nab-paclitaxel is significantly more effective than paclitaxel formulated as Cremophor EL (CrEL, Taxol, CrEL-paclitaxel), with almost double the response rate, increased time to disease progression and increased survival in second-line patients. The absence of CrEL from the formulation is associated with decreased neutropenia and rapid improvement of peripheral neuropathy with nab-paclitaxel, compared with CrEL-paclitaxel. For these reasons, nab-paclitaxel can be administered using higher doses of paclitaxel than that achievable with CrEL-paclitaxel, with shorter infusion duration and without the requirement for corticosteroid and antihistamine premedication to reduce the risk of solvent-mediated hypersensitivity reactions. Taken together, these studies have demonstrated that nab technology has increased the therapeutic index of paclitaxel compared with the conventional, solvent-based formulation.
Similar articles
-
Albumin-bound Paclitaxel: in metastatic breast cancer.Drugs. 2006;66(7):941-8. doi: 10.2165/00003495-200666070-00007. Drugs. 2006. PMID: 16740010
-
Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.Expert Opin Pharmacother. 2010 Jun;11(8):1413-32. doi: 10.1517/14656561003796562. Expert Opin Pharmacother. 2010. PMID: 20446855 Review.
-
Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.Crit Rev Oncol Hematol. 2014 Jan;89(1):62-72. doi: 10.1016/j.critrevonc.2013.08.001. Epub 2013 Aug 21. Crit Rev Oncol Hematol. 2014. PMID: 24071503 Review.
-
nab-Paclitaxel mechanisms of action and delivery.J Control Release. 2013 Sep 28;170(3):365-72. doi: 10.1016/j.jconrel.2013.05.041. Epub 2013 Jun 11. J Control Release. 2013. PMID: 23770008 Review.
-
Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration.Cancer Chemother Pharmacol. 2015 Oct;76(4):699-712. doi: 10.1007/s00280-015-2833-5. Epub 2015 Aug 1. Cancer Chemother Pharmacol. 2015. PMID: 26231955 Free PMC article.
Cited by
-
Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review.J Nanobiotechnology. 2024 Sep 28;22(1):587. doi: 10.1186/s12951-024-02859-w. J Nanobiotechnology. 2024. PMID: 39342211 Free PMC article. Review.
-
Efficacy and safety of nanoparticle albumin‑bound paclitaxel compared with solvent‑based paclitaxel in adjuvant therapy for breast cancer: A retrospective study.Oncol Lett. 2024 Aug 23;28(5):509. doi: 10.3892/ol.2024.14642. eCollection 2024 Nov. Oncol Lett. 2024. PMID: 39268162 Free PMC article.
-
Promoting chondrogenesis by targeted delivery to the degenerating cartilage in early treatment of osteoarthritis.Bioact Mater. 2024 Aug 15;40:624-633. doi: 10.1016/j.bioactmat.2024.08.004. eCollection 2024 Oct. Bioact Mater. 2024. PMID: 39247402 Free PMC article.
-
A Comprehensive Review of Nanoparticles: From Classification to Application and Toxicity.Molecules. 2024 Jul 25;29(15):3482. doi: 10.3390/molecules29153482. Molecules. 2024. PMID: 39124888 Free PMC article. Review.
-
Population pharmacokinetic and exposure-toxicity analyses of nab-paclitaxel after pegylated recombinant human granulocyte colony-stimulating factor administration in patients with metastatic breast cancer.Cancer Chemother Pharmacol. 2024 Oct;94(4):523-534. doi: 10.1007/s00280-024-04702-3. Epub 2024 Jul 31. Cancer Chemother Pharmacol. 2024. PMID: 39080018 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous